As lorlatinib remains the sole third-generation ALK TKI available for advanced ALK-positive NSCLC, there is a crucial requirement for further investigations on determining novel approaches to combat resistance that may arise during treatment progression. Here, ALK is linked to non-small cell lung carcinoma.